Alnylam Pharmaceuticals, Inc.

ALNYintermediary

Alnylam Pharmaceuticals is the pioneer and global leader in RNA interference (RNAi) therapeutics, a revolutionary approach to treating disease by silencing the genes that cause it. Its ATTR franchise has established RNAi as a validated drug modality, and its deep pipeline across cardiometabolic, CNS, and infectious diseases promises to expand the platform's reach.

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($2.4B)

Datos estáticos (cargando finanzas en tiempo real…)

ATTR Franchise (Amvuttra/Onpattro) (65%)

Royalties & Collaboration (Leqvio) (25%)

Other Pipeline Revenue (10%)

Composición de segmentos y clientes principales

Detalles del producto

Onpattro (Patisiran)30%

First FDA-approved RNAi therapeutic for hereditary ATTR amyloidosis

Amvuttra (Vutrisiran)40%

Subcutaneous RNAi treatment for ATTR polyneuropathy (quarterly dosing)

Leqvio (Inclisiran)30%

RNAi cholesterol-lowering drug partnered with Novartis

Relaciones en la Cadena de Suministro

Socios

Regeneron Pharmaceuticals

RNAi research collaboration

Impacto: Strategic R&D alliance

Eli Lilly and Company

Potential licensing discussions

Impacto: Pharma partnership potential

Competidores

Moderna, Inc.

RNA-based therapeutic modalities

Impacto: Competing RNA platforms

Contexto macro y de mercado

제약 / 바이오Noticias del sector

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Próximos catalizadores

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de Alnylam Pharmaceuticals, Inc. impulsado por IA.

Información de la Empresa

Sede Central

Cambridge, Massachusetts, USA

Fundación

2002

Empleados

2,800+

Sitio Web

alnylam.com

Estado del sector — 제약 / 바이오

Noticias del sector